In several tumor types, particularly breast, ovarian, pancreatic, and prostate cancers, a strong correlation was observed between increased gLOH and biallelic alterations in other HR genes beyond BRCA1 and BRCA2, including BARD1, PALB2, FANCC, RAD51C, and RAD51D. This evidence concerns the gene BARD1 and prostate carcinoma.